In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet ...

Biogen and Stoke Therapeutics have signed a deal to co-develop and sell Stoke’s experimental drug for Dravet syndrome, ...

While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to ...

Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...

Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is ...

Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...

Biogen Inc. CEO Christopher Viehbacher gave investors an overview of what type of deals the company is looking for Wednesday ...

Biogen forecast 2025 profit below Wall Street expectations on Wednesday, hurt by a strong dollar and fierce competition for ...

From my colleague Adam Feuerstein: Biogen and Stoke Therapeutics have signed a partnership agreement to co-develop and sell ...

Leqembi, which Biogen shares with the Japanese drugmaker Eisai, became the second drug proven to slow the progression of Alzheimer's to win approval in the U.S. in 2023. The therapy's launch has ...